C84.64
Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb
Clinical Classification Guidelines
Medical Intelligence & Overview
Anaplastic large cell lymphoma, ALK-positive (ICD-10 code C84.64), is a rare type of non-Hodgkin lymphoma primarily affecting the lymph nodes located in the axillary region (armpits) and upper limbs. This form of lymphoma is characterized by the presence of abnormal lymphocytes that multiply uncontrollably. The term 'ALK-positive' indicates the presence of a specific genetic abnormality involving the anaplastic lymphoma kinase (ALK) gene, which influences the behavior of the disease and its response to treatment. Typically seen in both children and young adults, this lymphoma forms a distinct category owing to its unique genetic features and treatment considerations.
Causes & Symptoms
Clinical Causes: Genetic mutations involving the ALK gene Chromosomal translocation affecting the ALK gene Potential environmental and immune factors, though specific causes are still under investigation
Key Symptoms: Swollen lymph nodes in the armpits and upper limbs Painless lumps or masses Fever or night sweats Unexplained weight loss Fatigue or weakness Frequent infections due to immune system involvement
Diagnostic & Treatment
Diagnosis Path: Diagnosing ALK-positive anaplastic large cell lymphoma involves a combination of physical examinations, imaging tests, tissue biopsies, and laboratory analyses. Key steps include: - **Physical exam** to identify swollen lymph nodes. - **Imaging studies** such as CT scans or PET scans to locate the affected areas. - **Lymph node biopsy** to examine the tissue microscopically for abnormal lymphocytes. - **Immunohistochemistry tests** to detect ALK protein expression. - **Molecular testing** like fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) to identify ALK gene alterations. These assessments help establish the presence of ALK-positive lymphoma and determine the extent of the disease.
Treatment Protocols: Treatment strategies for ALK-positive anaplastic large cell lymphoma often involve a combination of therapies aimed at eradicating cancer cells and managing symptoms. Common approaches include: - **Chemotherapy** regimens tailored to lymphoma, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or more intensive protocols. - **Targeted therapy** with ALK inhibitors like crizotinib, which specifically block the activity of the abnormal ALK protein. - **Radiation therapy** may be used in localized disease cases. - **Stem cell transplantation** might be considered for advanced or relapsed cases. - Supportive care to manage side effects and maintain quality of life. Treatment plans are personalized based on the patient’s overall health, disease stage, and response to initial therapies.
Clinical Advice & FAQs
Billing Guidance
Is C84.64 a billable ICD-10 code?
Yes, C84.64 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C84.64?
Clinical documentation must specify the nature of Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb and any associated comorbidities for accurate reporting.
Cite this Clinical Reference